Edition:
United Kingdom

Precision Therapeutics Inc (AIPT.OQ)

AIPT.OQ on NASDAQ Stock Exchange Capital Market

0.56USD
23 May 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$0.56
Open
$0.54
Day's High
$0.59
Day's Low
$0.53
Volume
67,924
Avg. Vol
20,496
52-wk High
$1.57
52-wk Low
$0.40

Latest Key Developments (Source: Significant Developments)

Precision Therapeutics Qtrly Loss Per Common Share $0.21
Wednesday, 15 May 2019 

May 15 (Reuters) - Precision Therapeutics Inc ::PRECISION THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 REVENUE FELL 38 PERCENT TO $255,000.QTRLY LOSS PER COMMON SHARE $0.21.  Full Article

Precision Therapeutics Unit, National Alopecia Areata Foundation Sign Services Agreement
Thursday, 18 Apr 2019 

April 18 (Reuters) - Precision Therapeutics Inc ::PRECISION THERAPEUTICS' SUBSIDIARY HELOMICS AND NATIONAL ALOPECIA AREATA FOUNDATION SIGN SERVICES AGREEMENT TO PROVIDE NEXT-GENERATION PATIENT REGISTRY FOR ALOPECIA AREATA RESEARCH.PRECISION THERAPEUTICS INC - TERMS AND FINANCIAL CONDITIONS OF AGREEMENT WERE NOT DISCLOSED..PRECISION THERAPEUTICS INC - SERVICES AGREEMENT BETWEEN ITS UNIT, HELOMICS AND NATIONAL ALOPECIA AREATA FOUNDATION.  Full Article

Precision Therapeutics Announces Proposed Public Offering Of Securities
Tuesday, 26 Mar 2019 

March 26 (Reuters) - Precision Therapeutics Inc ::PRECISION THERAPEUTICS INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF SECURITIES.PRECISION THERAPEUTICS INC - MAY ALSO USE A PORTION OF NET PROCEEDS TO REPAY INDEBTEDNESS..PRECISION THERAPEUTICS INC - ANNOUNCED A PROPOSED PUBLIC OFFERING OF ITS COMMON STOCK AND WARRANTS TO PURCHASE COMMON STOCK.  Full Article

Precision Therapeutics Extends Exchange Offer For Helomics Notes And Warrants
Thursday, 14 Mar 2019 

March 14 (Reuters) - Precision Therapeutics Inc ::PRECISION THERAPEUTICS EXTENDS EXCHANGE OFFER FOR HELOMICS NOTES AND WARRANTS.PRECISION THERAPEUTICS INC - EXTENSION OF EXPIRATION OF EXCHANGE OFFER.  Full Article

Precision Therapeutics Q3 Loss Per Share $0.19
Wednesday, 14 Nov 2018 

Precision Therapeutics Inc ::PRECISION THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.19.  Full Article

Precision Therapeutics Secures Rights To Novel Technology Designed To Develop Cancer Drugs
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Precision Therapeutics Inc ::PRECISION THERAPEUTICS SECURES RIGHTS TO NOVEL TECHNOLOGY DESIGNED TO DEVELOP DRUGS THAT TARGET SPECIFIC CANCER BY ITS MUTATION.PRECISION THERAPEUTICS SAYS ACQUIRED RIGHTS TO TECHNOLOGY FOR PROPRIETARY CULTURE MEDIA TO GROW OVARIAN CANCER CELL TYPES IN LAB FOR RESEARCH & TESTING.PRECISION THERAPEUTICS SAYS CO’S JV PARTNER HAS AGREED TO TERMS ON NON-EXCLUSIVE LICENSE TO THE TECHNOLOGY FROM A RESEARCH INSTITUTION - SEC FILING.  Full Article

Precision Therapeutics Q1 Loss Per Share $0.15
Tuesday, 15 May 2018 

May 15 (Reuters) - Precision Therapeutics Inc ::PRECISION THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.15.Q1 REVENUE $411,600 VERSUS $175,200.  Full Article

Precision Therapeutics Q4 Loss Per Share $0.43
Monday, 2 Apr 2018 

April 2 (Reuters) - Precision Therapeutics Inc ::PRECISION THERAPEUTICS REPORTS FISCAL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.43.Q4 REVENUE $220,300 VERSUS $139,600.  Full Article

Precision Therapeutics Unit Announces License Agreement With Cellbridge Inc
Wednesday, 21 Mar 2018 

March 21 (Reuters) - Precision Therapeutics Inc ::PRECISION THERAPEUTICS SUBSIDIARY, TUMORGENESIS, ANNOUNCES LICENSE AGREEMENT WITH CELLBRIDGE INCORPORATED.PRECISION THERAPEUTICS INC - CO'S UNIT, TUMORGENESIS SECURED A LICENSE AGREEMENT WITH CELLBRIDGE INCORPORATED​.  Full Article

Precision Therapeutics Forms Tumorgenesis Subsidiary
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Precision Therapeutics Inc ::PRECISION THERAPEUTICS FORMS TUMORGENESIS INC. SUBSIDIARY TO FOCUS ON THE NEXT GENERATION OF PATIENT DERIVED TUMOR MODELS.‍FORMED TUMORGENESIS TO DEVELOP A NEW, RAPID APPROACH TO GROWING TUMORS IN LABORATORY​.‍TESTING OF TUMORGENESIS PDX TUMORS TO TAKE PLACE IN COLLABORATION WITH HELOMICS, IN WHICH CO HAS 20% EQUITY STAKE​.IN NEGOTIATIONS WITH MEDICAL TECHNOLOGY COS TO LICENSE THEIR TECHNOLOGY TO ADVANCE TUMORGENESIS'S STRATEGIC PLAN​.  Full Article

No consensus analysis data available.